Table 1.
Clinicopathological patient features and their association with immunoreactivity
| Retrospective cohort | Prospective cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| Total (n = 95) | CD133 low (n = 74) | COX‐2 low (n = 20) | CD8+ TIL high (n = 23) | Total (n = 49) | CD133 low (n = 31) | COX‐2 low (n = 15) | CD8+ TIL high (n = 18) | |
| Age (years) * | 61·5(8·7) | 61·4(9·1) | 63·8(9·7) | 63·8(7·3) | 62·1(10·5) | 63·4(9·0) | 60·5(11·3) | 62·6(7·4) |
| Sex | ||||||||
| M | 66 (69) | 53 (72) | 12 (60) | 14 (61) | 34 (69) | 22 (71) | 10 (67) | 10 (56) |
| F | 29 (31) | 21 (28) | 8 (40) | 9 (39) | 15 (31) | 9 (29) | 5 (33) | 8 (44) |
| Pretreatment cT category | ||||||||
| cT3 | 91 (96) | 70 (95) | 18 (90) | 23 (100) | 47 (96) | 31 (100) | 15 (100) | 18 (100) |
| cT4 | 4 (4) | 4 (5) | 2 (10) | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) |
| Pretreatment cN category | ||||||||
| cN0 | 39 (41) | 32 (43) | 11 (55) | 12 (52) | 13 (27) | 8 (26) | 4 (27) | 4 (22) |
| cN1–2 | 56 (59) | 42 (57) | 9 (45) | 11 (48) | 36 (73) | 23 (74) | 11 (73) | 14 (78) |
| Pretreatment tumour size (mm) * | 45·4(14·5) | 44·2(14·0) | 45·9(17·3) | 42·3(12·8) | 43·1(13·9) | 41·8(15·0) | 40·3(12·5) | 41·7(8·7) |
| Distance to anal verge (mm) * | 44·5(18·3) | 42·3(19·1) | 42·3(18·4) | 45·0(19·8) | 44·5(24·2) | 41·6(26·0) | 42·7(27·1) | 52·2(21·0) |
| Tumour differentiation in pretreatment biopsy specimen | ||||||||
| Well/moderate† | 89 (94) | 68 (92) | 18 (90) | 20 (87) | 43 (88) | 25 (81) | 13 (87) | 17 (94) |
| Poor, mucinous or signet‡ | 6 (6) | 6 (8) | 2 (10) | 3 (13) | 6 (12) | 6 (19) | 2 (13) | 1 (6) |
| Pretreatment CEA level (ng/ml) | ||||||||
| ≤ 5·3§ | 69 (73) | 55 (74) | 16 (80) | 18 (78) | 31 (63) | 20 (65) | 9 (60) | 15 (83) |
| > 5·3 | 26 (27) | 19 (26) | 4 (20) | 5 (22) | 18 (37) | 11 (35) | 6 (40) | 3 (17) |
| Pretreatment CA19‐9 level (units/ml) | ||||||||
| ≤ 37§ | 82 (86) | 64 (86) | 18 (90) | 17 (74) | 40 (82) | 24 (77) | 12 (80) | 15 (83) |
| > 37 | 13 (14) | 10 (14) | 2 (10) | 6 (26) | 9 (18) | 7 (23) | 3 (20) | 3 (17) |
| Time from CRT to resection (days) * | 31·8(8·6) | 31·8(9·2) | 30·4(6·2) | 29·0(5·6) | 49·6(8·0) | 49·8(9·0) | 46·8(8·2) | 49·4(7·5) |
| Tumour differentiation in resected specimen * | ||||||||
| pCR | 3 (3) | 3 (4) | 3 (15) | 3 (13) | 8 (16) | 6 (19) | 4 (27) | 5 (28) |
| Well/moderate† | 85 (89) | 64 (86) | 15 (75) | 18 (78) | 36 (73) | 20 (65) | 10 (67) | 12 (67) |
| Poor, mucinous or signet‡ | 7 (7) | 7 (9) | 2 (10) | 2 (9) | 5 (10) | 5 (16) | 1 (7) | 1 (6) |
| pT category | ||||||||
| pCR | 3 (3) | 3 (4) | 3 (15) | 3 (13) | 8 (16) | 6 (19) | 4 (27) | 5 (28) |
| pTis and pT1–2 | 24 (25) | 20 (27) | 4 (20) | 9 (39) | 11 (22) | 8 (26) | 4 (27) | 5 (28) |
| pT3–4 | 68 (72) | 51 (69) | 13 (65) | 11 (48) | 30 (61) | 17 (55) | 7 (47) | 8 (44) |
| pN category | ||||||||
| pN0 | 46 (48) | 37 (50) | 13 (65) | 14 (61) | 32 (65) | 21 (68) | 9 (60) | 13 (72) |
| pN1–2 | 49 (52) | 37 (50) | 7 (35) | 9 (39) | 17 (35) | 10 (32) | 6 (40) | 5 (28) |
| TRG | ||||||||
| 0 | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 1 | 24 (25) | 15 (20) | 0 (0) | 2 (9) | 12 (24) | 10 (32) | 4 (27) | 4 (22) |
| 2 | 37 (39) | 27 (36) | 6 (30) | 7 (30) | 14 (29) | 6 (19) | 0 (0) | 1 (6) |
| 3 | 30 (32) | 29 (39) | 11 (55) | 11 (48) | 15 (31) | 9 (29) | 7 (47) | 8 (44) |
| 4 (pCR) | 3 (3) | 3 (4) | 3 (15) | 3 (13) | 8 (16) | 6 (19) | 4 (27) | 5 (28) |
Values in parentheses are percentages unless indicated otherwise;
*
values are mean(s.d.).
†
Well or moderately differentiated tubular adenocarcinoma;
‡
poorly differentiated or mucinous adenocarcinoma, or signet ring cell carcinoma.
§
Within normal limit. CD, cluster of differentiation; COX, cyclo‐oxygenase; TIL, tumour‐infiltrating lymphocyte; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; CRT, preoperative chemoradiotherapy; pCR, pathological complete response; TRG, tumour regression grade.